Trauma Surgery & Acute Care Open

# Weight-based enoxaparin thromboprophylaxis in young trauma patients: analysis of the CLOTT-1 registry

Sarah Lombardo (), <sup>1</sup> Marta McCrum, <sup>1</sup> M Margaret Knudson, <sup>2</sup> Ernest E Moore, <sup>3</sup> Lucy Kornblith (), <sup>2</sup> Scott Brakenridge (), <sup>4</sup> Brandon Bruns, <sup>5</sup> Mark D Cipolle, <sup>6</sup> Todd W Costantini, <sup>2</sup> Bruce Crookes, <sup>7</sup> Elliott R Haut (), <sup>8</sup> Andrew J Kerwin (), <sup>9</sup> Laszlo N Kiraly, <sup>10</sup> Lisa Marie Knowlton (), <sup>11</sup> Matthew J Martin, <sup>12</sup> Michelle K McNutt, <sup>13</sup> David J Milia, <sup>14</sup> Alicia Mohr, <sup>9</sup> Frederick Rogers, <sup>15</sup> Thomas Scalea, <sup>16</sup> Sherry Sixta, <sup>17</sup> David Spain (), <sup>18</sup> Charles E Wade, <sup>13</sup> George C Velmahos, <sup>19</sup> Ram Nirula, <sup>20</sup> Jade Nunez<sup>1</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi. org/10.1136/tsaco-2023-001230).

For numbered affiliations see end of article.

#### **Correspondence to**

Dr Sarah Lombardo; Sarah. Lombardo@hsc.utah.edu

Presented at the 51st Annual Meeting of the Western Trauma Association on February 20–25, 2022 in Big Sky, Montana.

Received 22 August 2023 Accepted 26 November 2023

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Lombardo S, McCrum M, Knudson MM, et al. Trauma Surg Acute Care Open 2024;**9**:e001230.

# ABSTRACT

**Introduction** Optimal venous thromboembolism (VTE) enoxaparin prophylaxis dosing remains elusive. Weightbased (WB) dosing safely increases anti-factor Xa levels without the need for routine monitoring but it is unclear if it leads to lower VTE risk. We hypothesized that WB dosing would decrease VTE risk compared with standard fixed dosing (SFD).

**Methods** Patients from the prospective, observational CLOTT-1 registry receiving prophylactic enoxaparin (n=5539) were categorized as WB (0.45–0.55 mg/kg two times per day) or SFD (30 mg two times per day, 40 mg once a day). Multivariate logistic regression was used to generate a predicted probability of VTE for WB and SFD patients.

Results Of 4360 patients analyzed, 1065 (24.4%) were WB and 3295 (75.6%) were SFD. WB patients were younger, female, more severely injured, and underwent major operation or major venous repair at a higher rate than individuals in the SFD group. Obesity was more common among the SFD group. Unadjusted VTE rates were comparable (WB 3.1% vs. SFD 3.9%; p=0.221). Early prophylaxis was associated with lower VTE rate (1.4% vs. 5.0%; p=0.001) and deep vein thrombosis (0.9% vs. 4.4%; p<0.001), but not pulmonary embolism (0.7% vs. 1.4%; p=0.259). After adjustment, VTE incidence did not differ by dosing strategy (adjusted OR (aOR) 0.75, 95% CI 0.38 to 1.48); however, early administration was associated with a significant reduction in VTE (aOR 0.47, 95% CI 0.30 to 0.74). **Conclusion** In young trauma patients, WB prophylaxis is not associated with reduced VTE rate when compared with SFD. The timing of the initiation of chemoprophylaxis may be more important than the dosing strategy. Further studies need to evaluate these findings across a wider age and comorbidity spectrum. Level of evidence Level IV, therapeutic/care management.

# BACKGROUND

Venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially lethal complication after injury. Endothelial dysfunction

# WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Three commonly used dosing strategies exist for the use of low-molecular weight heparin (LMWH) in the trauma population: (1) fixed standard dose, (2) weight-based dosing, and (3) anti-Xa-guided dosing. Numerous prospective observational and several systematic metaanalyses of the existing literature have failed to definitively establish the superiority of a particular dosing strategy.

# WHAT THIS STUDY ADDS

⇒ In young otherwise healthy trauma patients with at least one risk factor for venous thromboembolism (VTE), weight-based dosing of LMWH is not superior to a standard fixeddose strategy.

# HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Weight-based dosing of LMWH alone is not an appropriate strategy for improving VTE prevention in at-risk trauma patients. Future research should focus on evaluating the efficacy of anti-Xa-guided dosing as an alternative to weight-based administration.

resulting from trauma-induced local and systemic inflammatory signals significantly increases the risk of DVT and PE, even in baseline healthy individuals. Risk can be reduced through the use of mechanical and chemical VTE prophylaxis. A 2013 Cochrane database meta-analysis estimated the rate of DVT and PE in trauma patients receiving no prophylaxis at 8.7% and 3.3%, respectively. VTE prophylaxis of any kind (chemical, mechanical, or both) was associated with a significant reduction in DVT (relative risk [RR] 0.52, 95% confidence interval [CI] 0.32-0.84), but not PE.<sup>1</sup> The authors also reported that chemoprophylaxis in reducing overall DVT risk (RR 0.48, 95% CI 0.25-0.95).

Enoxaparin is the preferred agent for chemoprophylaxis in severely injured patients without contraindications for low-molecular weight

1

heparin (LMWH); however, controversy remains regarding optimal dosing strategies.<sup>2-4</sup> Early administration of LMWH has been associated with lower rates of DVT, PE, and in-hospital mortality when compared with unfractionated heparin (UH).<sup>5-7</sup> These studies typically used one of two fixed dosing regimens: 40 mg daily (once a day) or 30 mg every 12 hours (two times per day).<sup>5 8</sup> Recent recognition that these regimens may not achieve adequate biochemical prophylaxis, as measured by anti-Xa activity level,<sup>910</sup> has increased the support for alternative dosing strategies.<sup>3</sup> Obesity has been identified as a possible risk factor for subtherapeutic prophylaxis, leading to the adoption of weight-adjusted dosing schemes.<sup>10</sup> <sup>11</sup> Weight-adjusted enoxaparin prophylaxis is clearly linked to increased anti-Xa activity.<sup>12-14</sup> Despite evidence that patients with higher anti-Xa levels have reduced rates of VTE, a large meta-analysis of 24 studies was unable to correlate any type of dosing adjustment aimed at achieving target anti-Xa levels with a reduction in VTE incidence.<sup>14</sup> Additionally, a recent systematic review of 45 studies evaluating the effect of standard fixed-dose and weightbased (WB) chemoprophylaxis regimens on anti-Xa levels and VTE rates in obese trauma and surgical patients was unable to establish the superiority of a particular dosing strategy.<sup>15</sup>

In 2020, the Western Trauma Association (WTA) published updated guidelines for the selection of VTE prophylaxis in trauma patients, advocating for empirical higher doses of LMWH (40 mg two times per day) for young otherwise healthy patients without brain or spinal cord injury.<sup>3</sup> The authors also support the use of WB dosing strategies for the initial dosing of LMWH in patients greater than 100 kg. However, much of the cited literature for this topic relied on anti-Xa targets as a surrogate for VTE risk and did not correlate higher LMWH dosing or adjustment strategies with a reduction in VTE incidence.<sup>11 13 16-18</sup>

At present, it remains unclear whether WB dosing of enoxaparin, when compared with standard fixed dosing (SFD) strategies, reduces post-traumatic VTE in at-risk individuals. Early initiation of prophylaxis has consistently been shown to reduce the incidence of VTE events,<sup>19 20</sup> whereas recent studies have questioned whether delayed dose adjustment effectively reduces risk.<sup>14</sup> Anti-Xa-guided dosing requires numerous doses and laboratory draws over several days, a period during which VTE may have already occurred. Whether an initial WB dosing strategy is superior to SFD dosing has yet to be directly evaluated.

We performed a secondary analysis of the Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients, phase 1 (CLOTT-1) data, a large prospective multicenter study, to evaluate the effectiveness of WB enoxaparin compared with SFD enoxaparin for initial post-traumatic VTE prophylaxis. CLOTT-1 is an observational, multicenter study originally designed to describe and evaluate the clinical spectrum of DVT and PE in a young trauma population. We hypothesized that early initiation of WB dosing would be associated with a decreased risk of VTE when compared with patients receiving SFD enoxaparin prophylaxis.

#### METHODS CLOTT-1 population

CLOTT-1 was a multicenter, prospective, observational study of VTE after trauma. Trauma patients admitted to one of 17 participating American College of Surgeons Level 1 trauma centers between January 1, 2018 and December 31, 2020 were screened for enrollment. Inclusion criteria included ages 18–40 years, hospital length of stay (HLOS)  $\geq$ 48 hours, and at least one post-traumatic risk factor for VTE, resulting in a final cohort of 7903 patients.<sup>21</sup> Patient events and outcomes were recorded until discharge or for up to 30 days from admission.

Patient demographics and risk factors, height and weight, admission vitals, injury characteristics, laboratory values, measures of clinical care, and final disposition were extracted from the electronic medical record by participating sites and housed in the electronic data collection tool REDCap (Research Electronic Data Capture). Twelve post-traumatic risk factors for VTE were defined a priori: major head, chest or abdominal (Abbreviated Injury Scale (AIS) score  $\geq 3$ ) injury; spinal cord injury; pelvic fracture; lower extremity long bone fracture; major venous injury requiring repair; major operative procedure  $\geq 1$  hour and requiring general anesthesia; systolic blood pressure <90 mm Hg; mechanical ventilation  $\geq 4$  days; femoral venous catheter; and presence of central line.

The type, dose, and date of initiation of pharmacological VTE prophylaxis were extracted, along with dosing changes and missed doses. The data collection tool required that medication type and dosing for VTE prophylaxis was reported separately from medications and dosing intended for therapeutic antico-agulation. Any modification in dosing strategy (ie, agent, dose, etc) was captured along with the time, date, and the reason for the change. Some patients had multiple dosing changes during their hospital course; however, for this analysis the exposure to a dosing modification was simplified to a binary variable (ie, any change vs. no changes). The total number of missed doses of pharmacological prophylaxis was recorded for each patient. Each missed dose was also recorded individually, along with a time and date of the missed medication and the reported justification for holding the dose (eg, patient refusal).

Research by the CLOTT study group is supported by a grant from the Defense Medical Research and Development Program and managed by the National Trauma Institute and the Coalition for National Trauma Research.


# Study population and definitions

Patients from the CLOTT-1 registry receiving prophylactic enoxaparin during their hospital stay were identified (n=5539). Those with inferior vena cava filter present at the time of admission or placed during the hospital course, HLOS <3 days, or non-survivable injuries (defined as Injury Severity Score (ISS) of 75 or regional AIS score of 6) were excluded (figure 1). Observations with missing values for height or weight were also excluded due to inability to calculate patient body mass index (BMI). The lower and upper limits for BMI were set at 12 and 200 kg/m<sup>2</sup>, respectively. Patients were considered obese if BMI was  $\geq$ 30 kg/m<sup>2</sup>.

Prophylactic dosing strategy was classified post hoc as either WB (0.45–0.55 mg/kg two times per day) or standard (SFD; 30 mg two times per day or 40 mg once a day), based on the first received dose of VTE prophylaxis. Patients weighing between 50 and 70 kg who received enoxaparin 30 mg two times per day were assigned to WB because this is the appropriate WB dose for this weight range. Patients with non-standard, non-WB dosing were censored. Early prophylaxis was defined as receipt of first dose of VTE chemoprophylaxis within 24 hours of hospital admission.

# Statistical analysis

The primary outcome was incidence of VTE. The secondary outcomes of interest were incidence of DVT and PE, and rates of in-hospital complications attributable to chemoprophylaxis, including worsening of intracranial hemorrhage, solid organ



**Figure 1** Study flow diagram. AIS, Abbreviated Injury Scale; BID, two times per day; DVT, deep vein thrombosis; HLOS, hospital length of stay; ISS, Injury Severity Score; IVC, inferior vena cava; SFD, standard fixed dosing; WB, weight based.

bleeding, or other sites of new or worsened bleeding (ie, wound, gastrointestinal, genitourinary). Diagnosis of DVT and PE were confirmed by standard imaging techniques. The date and results of extremity duplex ultrasonography and CT chest angiography during the hospital course were recorded. As this was an observational study, no study protocol directed the screening, prophylaxis, or treatment of patients with suspected VTE.

The study was performed on an intention-to-treat basis, with the assignment of WB versus SFD made based on the first recorded dose of prophylactic enoxaparin. Univariate and bivariate analyses used common statistical tests to compare WB and SFD populations. Mean and SD are reported for continuous variables with normal distribution, and differences compared using the independent samples t-test. Non-parametric variables are summarized by median and IQR and evaluated using the Wilcoxon rank-sum test. Categorical variables are reported as percentages and compared using  $\chi^2$  test or Fisher's exact test, as appropriate.

Multivariate logistic regression models for VTE, DVT, and PE were developed to explore the effect of WB enoxaparin dosing, after adjusting for known risk factors. All potential risk factors that were significant at p < 0.2 were entered into a forward stepwise logistic regression model. Clustering at the hospital level was applied to account for institutional differences not otherwise captured by this dataset (eg, VTE screening protocols). Variables retained in the final models are reported in the results, along with model diagnostics, including area under the receiver

# Table 1 Patient demographics and VTE risk factors

5 1			
	Weight based (n=1065)	Standard (n=3295)	P value
Age (years; mean, SD)	28 (7)	29 (6)	<0.001
Female*	35.7%	23.8%	< 0.001
Race/ethnicity*			0.008
Caucasian	40.5%	45.1%	
African American	32.2%	31.2%	
Latinx	17.4%	13.6%	
Other	9.9%	10.1%	
Obesity (BMI≥30 kg/m²)	3.4%	30.4%	< 0.001
Medical history*			
VTE	0.9%	0.7%	0.687†
Cancer	0.1%	0.3%	0.468†
Blunt mechanism*	74.6%	75.7%	0.436
ISS (mean, SD)	18 (11)	17 (11)	0.002
VTE risk factors			
Head AIS≥3	27.0%	23.5%	0.020
Chest AIS≥3	32.4%	30.8%	0.321
Abdomen AIS≥3	24.1%	21.8%	0.111
Spinal cord injury	4.3%	3.7%	0.339
Pelvic fracture	21.4%	20.2%	0.413
Lower extremity long bone fracture	35.8%	37.4%	0.334
Major venous repair	6.1%	4.5%	0.038
Major operation	81.1%	74.1%	< 0.001
SBP<90 mm Hg	7.0%	6.2%	0.379
Ventilator >4 days	12.5%	10.5%	0.076
Femoral venous catheter	6.1%	4.7%	0.077
Central line	11.4%	9.1%	0.030
			-

\*Missingness: female n=1; race/ethnicity n=10; history of VTE n=18; history of cancer n=16; mechanism n=2.

†Fisher's exact test.

AIS, Abbreviated Injury Scale; BMI, body mass index; ISS, Injury Severity Score; SBP, systolic blood pressure; VTE, venous thromboembolism.

operating characteristic curve and Hosmer-Lemeshow goodnessof-fit testing. Adjusted ORs (aOR) and 95% CIs are reported.


A substantial number of patients received a non-WB, non-SFD enoxaparin for chemoprophylaxis (n=452, 9.4%). While these observations were censored for the primary analysis, on closer review of the data we noted that 85.0% of this censored cohort received 40 mg two times per day. Recent publications have advocated for higher empirical doses of enoxaparin in trauma patients with moderate or greater risk for VTE and no contraindications to LMWH.<sup>3</sup> As such, we completed two additional analyses in which patients receiving 30 or 40 mg two times per day were classified as WB if (1) reported patient weight was <50 kg (n=68), which represented overdosing for prophylaxis, or (2) reported patient weight was  $\geq$ 70 kg (n=277), consistent with a weight-stratified approach. The results of these sensitivity analyses did not alter our findings, the details of which can be found in online supplemental tables S1 and S2.

Incorporating feedback from reviewers of the initial article two post hoc analyses were completed; one focusing on the relationship between enoxaparin dosing and VTE risk of obese patients, and the second being a time-to-event analysis of in-hospital DVTs. The subgroup analysis of obese patients (BMI $\geq$ 30) used stepwise multivariate logistic regression techniques with clustering by hospital site, as previously described. It should be noted that of the 1038 obese patients in this subgroup, only 36 received appropriate WB enoxaparin prophylaxis. Findings of copyright.

 Table 2
 Characteristics of prophylactic enoxaparin dosing by group assignment

Weight based (n=1065)	Standard (n=3295)	P value
n/a	31.7%	
0.2%	n/a	
78.1%	68.3%	
20.7%	n/a	
0.9%	n/a	
0.1%	n/a	
53.2%	53.9%	0.694
44.4%	39.5%	0.004
2 (1, 3)	2 (1, 3)	0.593*
47.0%	42.9%	0.023
36.6%	38.9%	0.185
5.5%	4.8%	0.403
1.5%	1.1%	0.323
13.8%	16.3%	0.052
1 (1, 2)	1 (1, 1)	0.349*
	(n=1065) n/a 0.2% 78.1% 20.7% 0.9% 0.1% 53.2% 44.4% 2 (1, 3) 47.0% 36.6% 5.5% 1.5% 1.5%	(n=1065)         (n=3295)           n/a         31.7%           0.2%         n/a           78.1%         68.3%           20.7%         n/a           0.9%         n/a           0.1%         n/a           53.2%         53.9%           44.4%         39.5%           2 (1, 3)         2 (1, 3)           47.0%         42.9%           36.6%         38.9%           5.5%         4.8%           1.5%         1.1%           "13.8%         16.3%

this analysis are reported in online supplemental table S3, and again did not significantly alter the conclusions of this study. For the time-to-event analysis, the event was defined as a positive finding of DVT on venous duplex examination at any location. Time to event in days was calculated by subtracting the date of



**Figure 2** Unadjusted venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) rates by cohort. Early prophylaxis was associated with significantly lower rates of VTE and DVT relative to delayed initiation of prophylaxis for both weight-based (WB) ( $\blacktriangle$ ) and standard fixed dosing (SFD) ( $\blacklozenge$ ) groups.

a positive examination from the date of hospital admission, and patients were censored at the time of death or hospital discharge. Differences between groups were evaluated by log-rank test and Cox proportional hazard. The assumption of proportionality was evaluated by log-log plot and Schoenfeld residuals.

Power calculations were completed using a range of incidence rates obtained from published studies, as well as limited data on the patient population used in this study. The purpose of this calculation was to assist in our interpretation of the results, and not to direct the analytical strategy. Previously reported VTE rates in trauma patients have ranged widely; the highest rates are typically among severely injured patients with multiple VTE risk factors and in studies using routine VTE surveillance practices.<sup>5</sup><sup>13</sup> As such, we performed several power calculations with sensitivity analysis to account for this known variation. The expected VTE rate for SFD enoxaparin dosing was evaluated at 4%, 7%, 12%, and 20%.<sup>11 13 15</sup> The hypothesized reduction in VTE with WB dosing was tested at 15%, 30% and 50%, based on reported effects of WB dosing strategies on both anti-Xa levels and VTE rates.<sup>11 18 22</sup> The type 1 error was set at 0.05, and power at 0.80. The 1:3 ratio of WB to SFD patients was used in these calculations based on the observed ratio from initial review of these data. The results of the analysis are included in online supplemental table S4. Based on this evaluation, this study is powered to detect a 30% difference in VTE rate between treatment groups assuming a baseline VTE rate of at least 12% in the SFD group.

Data were cleaned and analyzed using the statistical package Stata for Mac, V.16.1 (StataCorp, College Station, TX). The data collection and initial analysis of the CLOTT-1 registry was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Defense Medical Research and Development Program (award number: W81XWH-17-1-0673). There is no additional funding to report for this secondary analysis. This article was drafted in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist for retrospective observational studies (online supplemental table S5).

# RESULTS

# **Study population**

Of the 7903 patients captured in the CLOTT study, 5539 received prophylactic dosing of enoxaparin during their admission. 727 patients met exclusion criteria (figure 1), and 452 patients were further excluded due to non-standard dosing. The final cohort consisted of 4360 patients: 1065 (24.4%) received WB and 3295 (75.6%) received SFD enoxaparin DVT chemoprophylaxis.

WB patients were younger, more likely to be female, and less likely to be obese (table 1). Mean ISS was statistically higher for the WB cohort. With respect to the 12 predefined VTE risk factors, groups were comparable except head AIS  $\geq$ 3, major operation, major venous injury, and presence of central line, all of which were more common in the WB group.

#### **Enoxaparin dosing**

The majority of patients (78.1%) in the WB group received 30 mg two times per day (table 2). In the SFD group 68.3% of patients received 30 mg two times per day and 31.7% 40 mg once a day. The first dose of chemoprophylaxis was administered within 24 hours of admission for the majority of patients (WB 53.2% vs. SFD 53.9%). Changes to dosing regimens occurred in 13.8% of the WB group and 16.3% of the SFD group. There were 4358 reported missed doses among 1773 patients (mean 2.7, range

	VTE	DVT	PE
Model diagnostics			
Observations (n)	4268	4268	4226
AUC	0.807	0.805	0.848
Hosmer-Lemeshow GOF	0.124	0.641	0.458
Variables: aOR (95% CI)			
Weight-based dosing	0.75 (0.38, 1.48)	0.86 (0.40, 1.87)	0.73 (0.38, 1.40)
Obesity	1.54 (0.99, 2.39)	1.49 (0.88, 2.53)	1.83 (0.83, 4.03)
Age	1.03 (1.01, 1.05)	1.04 (1.01, 1.06)	_
ISS	1.02 (1.01, 1.04)	1.02 (1.00, 1.04)	1.03 (1.00, 1.05)
Latinx	-	1.70 (1.08, 2.66)	-
Race, other	0.70 (0.41, 1.19)		
Medicare, Medicaid	-	_	0.54 (0.27, 1.06)
Uninsured, self-pay	-	0.49 (0.17, 1.43)	1.66 (0.95, 2.90)
Early prophylaxis (≤24 h)	0.47 (0.30, 0.74)	0.40 (0.25, 0.65)	0.60 (0.28, 1.28)
Red blood cell (RBC) transfusion	1.06 (1.02, 1.11)	1.06 (1.02, 1.10)	1.06 (1.01, 1.12)
Penetrating mechanism	1.42 (0.92, 2.20)	1.37 (0.87, 2.13)	1.80 (0.87, 3.75)
Tranexamic acid (TXA)	-	1.56 (0.89, 2.71)	-
VTE risk factors			
Head AIS ≥3	-	_	0.51 (0.24, 1.08)
Chest AIS ≥3	1.49 (0.95, 2.34)	1.51 (1.01, 2.27)	-
Shock at admission	_	0.65 (0.42, 1.01)	_
Lower extremity long bone fracture	1.34 (0.94, 1.93)	_	1.69 (0.88, 3.25)
Spinal cord injury	1.73 (0.96, 3.10)	_	2.31 (1.10, 4.43)
Central venous catheter	2.55 (1.29, 5.05)	2.32 (0.99, 5.41)	3.00 (1.29, 6.95)
Femoral catheter	2.07 (1.11, 3.85)	2.04 (0.94, 4.42)	1.55 (0.89, 2.72)
Prolonged mechanical ventilation ( $\geq$ 4 days)	_	_	2.11 (0.96, 4.63)

Unmeasured variation in institutional practices was controlled for by clustering at the level of the hospital site. Omitted values (–) indicate variables that were not retained in the final stepwise model. Statistically significant values are in **bold**.

AIS, Abbreviated Injury Scale; aOR, adjusted OR; AUC, area under the receiver operating characteristic curve; DVT, deep vein thrombosis; GOF, goodness of fit; ISS, Injury Severity Score; PE, pulmonary embolism; VTE, venous thromboembolism.

1–39), with a significantly higher rate of missed doses in the WB group (44.4% vs. 39.5%). The most common reasons for missed doses were need for procedural intervention and patient refusal, which were more frequent in the WB group (p=0.023; table 2). Concern for bleeding or bleed-related complications were less commonly cited justifications and did not differ by prophylaxis strategy. There was a higher rate of reported regimen changes in the SFD group (p=0.052), but most patients (86.2% for WB and 83.7% for SFD) did not have alterations in chemoprophylaxis agent or dose.

### **Unadjusted outcomes**


The composite VTE rate for the study population was 3.7% (n=162; DVT 2.8%, PE 1.2%). VTE incidence was 3.1% (n=33; DVT 2.5%, PE 1.0%) in the WB group and 3.9% (n=129; DVT 2.9%, PE 1.3%) in the SFD group, which did not differ significantly (p=0.221) (figure 2). Early prophylaxis was associated with significantly lower rates of VTE (1.9%  $\leq$ 24 hours vs. 5.8% >24 hours, p<0.001), DVT (1.3% vs. 4.7%, p<0.001), and PE (0.8% vs. 1.7%, p=0.004). By dosing strategy, the differences in VTE, DVT, and PE remained significant for SFD patients receiving early prophylaxis, whereas only the rates of VTE and DVT were significantly lower among WB patients with early prophylaxis (figure 2). Among those receiving early prophylaxis, there was no difference in VTE, DVT or PE rates among WB versus SFD cohorts (online supplemental table S6). VTE and DVT were more common among obese patients. Obese patients

receiving WB prophylaxis had significantly higher rates of DVT (11.1% vs. 3.0%, p=0.027), but not VTE or PE (online supplemental table S6). In the obese population early prophylaxis was also associated with decreased incidence of VTE (2.7% vs. 7.5%, p<0.001), DVT (1.7% vs. 5.6%, p<0.001), and PE (1.1% vs. 2.8%, p=0.031).

Complications attributable to chemoprophylaxis were uncommon. Enoxaparin exposure was associated with progression of intracranial hemorrhage in seven patients (0.2%), and worsening or new solid organ bleeding in four patients (0.1%). Overall, there was a 1.0% rate of chemoprophylaxis-associated complication within this cohort, and no difference was detected between groups (online supplemental table S6).

# **Adjusted outcomes**

After adjustment, VTE, DVT, and PE rates did not differ by dosing strategy (table 3). For all outcomes, injury severity (ISS) and red blood cell (RBC) transfusion volume were significant positive predictors. Obesity was associated with an increased risk of VTE, DVT, and PE, but this did not reach statistical significance in any model. The variable for missed doses of VTE prophylaxis did not meet prespecified inclusion criteria for any model and was omitted for all outcomes. Early initiation of chemoprophylaxis was associated with a 53% reduction in the likelihood of VTE (aOR 0.47, 95% CI 0.30 to 0.74). This is attributable to a reduction in the odds of DVT (aOR 0.40, 95%



**Figure 3** Kaplan-Meier curve of the full cohort showing time to positive venous duplex examination (deep vein thrombosis (DVT) positive) within 30 days of admission. Patients who died or discharged prior to 30 days were censored.

CI 0.25 to 0.65), as early prophylaxis was not an independent predictor of PE on multivariate analysis.

#### Time-to-event analysis

There were 110 positive venous duplex examinations, which were similarly distributed between groups (WB 2.1% vs. SFD 2.7%; p=0.274). Unadjusted survival curve and log-rank test failed to detect a significant difference in time to event (figure 3; p=0.522). Review of the Kaplan-Meier curve (figure 3) showed a delayed separation of the WB and SFD groups at approximately hospital day 10, raising concern for non-proportional hazard over time. Evaluation of the multivariate Cox model confirmed non-proportionality by log-log plot and Schoenfeld residuals for both the full cohort and for a subgroup of patients with HLOS  $\geq$ 10 days. The assumption of proportionality was preserved in a subgroup of patients with HLOS <10 days; however, the treatment effect remained non-significant.

#### DISCUSSION

The results of our study showed no difference in efficacy of WB versus SFD enoxaparin for VTE prophylaxis in young trauma patients. However, early initiation of prophylaxis was protective against VTE regardless of dosing strategy. Other significant risk factors for VTE within this cohort include increased age, obesity, more severe injury (higher ISS, RBC transfusion volume), and two of the 12 predefined VTE risk factors (presence of femoral or other central venous line). Interestingly, missed doses of VTE chemoprophylaxis were more common among the WB cohort, but were not independently predictive of worse clinical outcomes.

Effective prophylaxis against post-traumatic VTE with LMWH may not be dose dependent in young otherwise healthy trauma patients. Subtherapeutic anti-Xa activity is common among patients receiving traditional dosing regimens and has been associated with an elevated risk for VTE.<sup>910</sup> New strategies seeking to improve these outcomes include use of higher fixed doses (ie, 40 mg two times per day),<sup>3</sup> WB or weight-stratified dosing,<sup>13 18</sup> and enoxaparin dosing titrated to anti-Xa activity level.<sup>22 23</sup> A shared characteristic of all non-traditional dosing schemes is that most patients ultimately receive larger doses of LMWH. While higher doses do result in a greater percentage

of patients achieving biochemical prophylaxis targets by anti-Xa activity level,<sup>11</sup> no single strategy has been proven to lower the risk of post-traumatic VTE relative to traditional dosing.<sup>15</sup> Our evaluation of the CLOTT-1 database offers the largest prospective, observational assessment of initial WB LMWH dosing strategies for VTE prophylaxis in a trauma population. The absence of anti-Xa levels in this dataset precluded biochemical assessment of adequate prophylaxis. However, the lack of evidence to support anti-Xa as an accurate measure of VTE prophylaxis highlights the importance of reporting on clinically relevant events. Our null result is consistent with the conclusions of several recent reviews that found insufficient evidence to back the adoption of non-traditional dosing strategies to achieve the clinical goal of reducing post-traumatic VTE risk.<sup>4</sup><sup>24</sup>

Unlike the controversy surrounding dosing strategies, early initiation of chemoprophylaxis clearly decreases the risk of VTE after trauma.<sup>25</sup> A 2020 evaluation of >79 000 patients from the Michigan Trauma Quality Improvement Program (MTQIP) database used multivariate logistic modeling to optimize the comparison of patients receiving their first dose of VTE prophylaxis <24 hours, 24 to <48 hours, and  $\geq$ 48 hours after hospital admission.<sup>26</sup> Delays in prophylaxis were associated with increased VTE risk relative to the earliest group (<24 hours). Patients receiving their first dose  $\geq$ 48 hours from admission had a greater than twofold increased risk of VTE (OR 2.35, p < 0.001). Similarly, we found early initiation of prophylaxis with 24 hours of admission to confer a 53% risk reduction in VTE, with the protective benefit persisting regardless of dosing strategy. The 2020 MTQIP study did not exclude patients who received UH, but did adjust for the type of pharmacological agent, finding LMWH to be superior to UH with respect to VTE risk (OR 0.62, p<0.001).<sup>26</sup> Taken together, these findings suggest that both agent and timing may be more important than dosing scheme alone. The low rate of bleeding complications was anticipated based on existing literature and again highlights the safety of early LMWH in trauma populations.<sup>25 27</sup> Our results reinforce current guidelines recommending prophylaxis be started as soon as possible for stable patients without contraindications.<sup>34</sup>

Recently, the correlation between post-traumatic DVT and pulmonary clots has been called into question.<sup>28-30</sup> The primary analysis of the CLOTT-1 data sought to characterize posttraumatic pulmonary thrombosis (PT) as an entity that is clinically distinct from DVT and PE.<sup>21</sup> Supported by their findings that patients with PT have specific injury patterns and clinical risk factors, the authors raise intriguing questions as to the ability of post-traumatic VTE prophylaxis to prevent such events. Of the 157 patients with PE on chest imaging, 117 (74.5%) had no evidence of DVT and were thus classified as PT.<sup>21</sup> If a similar proportion of PE-positive patients in our subanalysis are assumed to in fact have PT, we can interpret the lack of effect of early prophylaxis in our risk-adjusted model for PE as further evidence that the pathophysiology of PT is distinct from DVT and PE. As such, future investigations evaluating the effects of VTE prophylaxis should aim to differ between PE and PT when defining clinical outcomes.

#### Limitations

This study has limitations that are inherent to its observational nature and may limit broad generalizability of our findings. Patients included in this analysis are young and lack many of the comorbidities and risk factors common among older trauma populations. Obesity was uncommon in our WB group. Though we failed to identify a protective benefit of WB dosing in the obese cohort, our multivariate analysis may be underpowered to detect meaningful differences in dosing strategy that may otherwise exist. Variability in institutional practices with respect to VTE prophylaxis and DVT screening is likely significant across the 17 contributing centers. We attempted to control for the effects of unmeasured site-specific difference in our adjusted analysis. Due to the absence of anti-Xa activity data, we were unable to assess dosing strategy or clinical events with respect to this commonly reported measure. Most importantly, we recognized that 85% of patients who did not classify as either WB or SFD received enoxaparin 40 mg two times per day, an increasingly common fixed prophylactic dose promoted by WTA's 2020 guidelines.<sup>3</sup> As such, we performed two post hoc analyses that considered these patients to have received WB enoxaparin if their weight was (1) < 50 kg (overdosed) or (2)  $\ge$  70 kg (weight stratified). The results of this additional work did not alter our conclusions and are included in online supplemental tables 1 and 2. Finally, despite this being among the largest prospective evaluations of WB VTE prophylaxis in trauma yet published, due to the low baseline incidence of VTE in patients receiving SFD enoxaparin we may have been underpowered to detect any small incremental benefit that WB dosing might afford.

# CONCLUSION

We found no difference in rates of VTE between WB and standard dosing strategy in a young trauma population. Early administration had a significant effect, associated with 53% reduction in odds of VTE. Both dosing strategies appear to be safe, with comparably low risks of bleed progression. Obesity is a known risk factor for VTE; however, our understanding of the complex relationship between higher body mass, post-traumatic physiology, and optimal VTE prophylaxis strategies remains incomplete. Further studies are needed to evaluate the risk-benefit profile of LMWH dosing strategies in older and obese trauma populations, while paying close attention to timing of prophylaxis initiation and other known VTE risk factors.

#### Author affiliations

- <sup>1</sup>Surgery, University of Utah, Salt Lake City, Utah, USA
- <sup>2</sup>Surgery, University of California San Francisco, San Francisco, California, USA
- <sup>3</sup>Denver Health Medical Center, Denver, Colorado, USA
- <sup>4</sup>Department of Surgery, University of Washington, Seattle, Washington, USA
- <sup>5</sup>Department of Surgery, UT Southwestern Medical School, Dallas, Texas, USA
- <sup>6</sup>Lehigh Valley Health Network, Allentown, Pennsylvania, USA
- <sup>7</sup>Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
- <sup>8</sup>Surgery, Johns Hopkins University, Baltimore, Maryland, USA
- <sup>9</sup>Surgery, University of Florida College of Medicine–Jacksonville, Jacksonville, Florida, USA
- <sup>10</sup>Oregon Health & Science University, Portland, Oregon, USA
- <sup>11</sup>General Surgery, Stanford University, Stanford, California, USA
- <sup>12</sup>Division of Trauma and Surgical Critical Care, LAC+USC Medical Center, Los Angeles, California, USA
- <sup>13</sup>Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA <sup>14</sup>Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- <sup>15</sup>Lancaster General Health, Lancaster, Pennsylvania, USA
- <sup>16</sup>University of Maryland School of Medicine, Baltimore, Maryland, USA
- <sup>17</sup>St Anthony Hospital & Medical Campus, Lakewood, Colorado, USA
- <sup>18</sup>Surgery, Stanford University, Stanford, California, USA
- <sup>19</sup>Massachusetts General Hospital, Boston, Massachusetts, USA
- <sup>20</sup>University of Utah School of Medicine, Salt Lake City, Utah, USA

**Contributors** Literature search: SL, JN. Study design: SL, RN, JN. Data collection and original study design: MMK, LK, SB, BB, MDC, TWC, BC, ERH, AJK, LNK, LMK, MJM, MKM, DJM, AM, FR, SS, DS, CEW, RN. Data analysis: SL. Data interpretation: SL, MM, JN, RN. Writing: SL, JN. Critical revision: SL, MM, JN, RN. Guarantor: SL.

**Funding** The data collection and initial analysis of the CLOTT-1 registry was supported by the Office of the Assistant Secretary of Defense for Health Affairs

through the Defense Medical Research and Development Program (award number: W81XWH-17-1-0673) (MMK, principal investigator).

Competing interests SL reported receiving fees from Oakstone Publishing for completed work. LK reported receiving personal fees from Cerus SAB outside the submitted work. BB reported receiving grants from the US Department of Defense during the conduct of the study. MDC reported receiving grants from the US Army Medical Research Acquisition Activity during the conduct of the study. BC reported receiving grants from the National Trauma Institute during the conduct of the study. ERH reported receiving grants from the US Army Medical Research Acquisition Activity during the conduct of the study and grants from the Agency for Healthcare Research and Quality, the Patient-Centered Outcomes Research Institute, the National Heart, Lung, and Blood Institute, and the Henry M Jackson Foundation for the Advancement of Military Medicine, and speaker fees from Vizient (paid speaker for the Vizient Hospital Improvement Innovation Network VTE Prevention Acceleration Network) outside the submitted work. AJK reported receiving grants from the US Army Medical Research Acquisition Activity during the conduct of the study. LNK reported receiving grants from the Coalition for National Trauma Research of the US Department of Defense during the conduct of the study. MJM reported receiving grants from the US Department of Defense during the conduct of the study. AM reported receiving grants from the National Trauma Institute during the conduct of the study. CEW reported having stock in Decisio and receiving grants from Grifols outside the submitted work. GCV reported receiving grants from the National Institutes of Health during the conduct of the study.

#### Patient consent for publication Not applicable.

**Ethics approval** Investigational Review Board (IRB) approval was obtained individually at each site contributing to the CLOTT-1 registry, and separate IRB approval was obtained at the University of Utah for this analysis (IRB 00157535).

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. Data may be available upon reasonable request from Dr. Knudson (peggy.knudson@ucsf. edu).

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID** iDs

Sarah Lombardo http://orcid.org/0000-0002-1132-0881 Lucy Kornblith http://orcid.org/0000-0002-1861-9691 Scott Brakenridge http://orcid.org/0000-0002-7327-3718 Elliott R Haut http://orcid.org/0000-0001-7075-771X Andrew J Kerwin http://orcid.org/0000-0003-4372-5813 Lisa Marie Knowlton http://orcid.org/0000-0001-6046-5035 David Spain http://orcid.org/0000-0002-0477-7613

# REFERENCES

- Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Thromboprophylaxis for trauma patients. *Cochrane Database Syst Rev* 2013;2013:CD008303.
- 2 Guyatt GH, Eikelboom JW, Gould MK, Garcia DA, Crowther M, Murad MH, Kahn SR, Falck-Ytter Y, Francis CW, Lansberg MG, *et al.* Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:e1855–e1945.
- 3 Ley EJ, Brown CVR, Moore EE, Sava JA, Peck K, Ciesla DJ, Sperry JL, Rizzo AG, Rosen NG, Brasel KJ, et al. Updated guidelines to reduce venous thromboembolism in trauma patients: a Western Trauma Association critical decisions algorithm. J Trauma Acute Care Surg 2020;89:971–81.
- 4 Rappold JF, Sheppard FR, Carmichael Ii SP, Cuschieri J, Ley E, Rangel E, Seshadri AJ, Michetti CP. Venous thromboembolism prophylaxis in the trauma intensive care unit: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. *Trauma Surg Acute Care Open* 2021;6:e000643.

# **Open** access

- 5 Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *N Engl J Med* 1996;335:701–7.
- 6 Byrne JP, Geerts W, Mason SA, Gomez D, Hoeft C, Murphy R, Neal M, Nathens AB. Effectiveness of low-molecular-weight heparin versus Unfractionated heparin to prevent pulmonary embolism following major trauma: a propensity-matched analysis. J Trauma Acute Care Surg 2017;82:252–62.
- 7 Jacobs BN, Cain-Nielsen AH, Jakubus JL, Mikhail JN, Fath JJ, Regenbogen SE, Hemmila MR. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. J Trauma Acute Care Surg 2017;83:151–8.
- 8 Bush S, LeClaire A, Hampp C, Lottenberg L. Review of a large clinical series: onceversus twice-daily enoxaparin for venous thromboembolism prophylaxis in high-risk trauma patients. J Intensive Care Med 2011;26:111–5.
- 9 Malinoski D, Jafari F, Ewing T, Ardary C, Conniff H, Baje M, Kong A, Lekawa ME, Dolich MO, Cinat ME, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010;68:874–80.
- 10 Costantini TW, Min E, Box K, Tran V, Winfield RD, Fortlage D, Doucet J, Bansal V, Coimbra R. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. *J Trauma Acute Care Surg* 2013;74:128–33;
- 11 Berndtson AE, Costantini TW, Lane J, Box K, Coimbra R. If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. J Trauma Acute Care Surg 2016;81:1095–100.
- 12 Ludwig KP, Simons HJ, Mone M, Barton RG, Kimball EJ. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. *Ann Pharmacother* 2011;45:1356–62.
- 13 Bickford A, Majercik S, Bledsoe J, Smith K, Johnston R, Dickerson J, White T. Weightbased enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. *Am J Surg* 2013;206:847–51.
- 14 Verhoeff K, Raffael K, Connell M, Kung JY, Strickland M, Parker A, Anantha RV. Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: a systematic review and meta-analysis. J Trauma Acute Care Surg 2022;93:e61–70.
- 15 Shaikh S, Boneva D, Hai S, McKenney M, Elkbuli A. Venous thromboembolism chemoprophylaxis regimens in trauma and surgery patients with obesity: a systematic review. J Trauma Acute Care Surg 2020;88:522–35.
- 16 Rodier SG, Bukur M, Moore S, Frangos SG, Tandon M, DiMaggio CJ, Ayoung-Chee P, Marshall GT. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. *Eur J Trauma Emerg Surg* 2021;47:145–51.
- 17 Walker CK, Sandmann EA, Horyna TJ, Gales MA. Increased enoxaparin dosing for venous thromboembolism prophylaxis in general trauma patients. *Ann Pharmacother* 2017;51:323–31.

- 18 Nunez JM, Becher RD, Rebo GJ, Farrah JP, Borgerding EM, Stirparo JJ, Lauer C, Kilgo P, Miller PR. Prospective evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of antixa levels is improved. *Am Surg* 2015;81:605–9.
- 19 Lu VM, Alvi MA, Rovin RA, Kasper EM. Clinical outcomes following early versus late pharmacologic thromboprophylaxis in patients with traumatic intracranial hemorrhage: a systematic review and meta-analysis. *Neurosurg Rev* 2020;43:861–72.
- 20 Lamb T, Lenet T, Zahrai A, Shaw JR, McLarty R, Shorr R, Le Gal G, Glen P. Timing of pharmacologic venous thromboembolism prophylaxis initiation for trauma patients with nonoperatively managed blunt abdominal solid organ injury: a systematic review and meta-analysis. *World J Emerg Surg* 2022;17:19.
- 21 Knudson MM, Moore EE, Kornblith LZ, Shui AM, Brakenridge S, Bruns BR, Cipolle MD, Costantini TW, Crookes BA, Haut ER, *et al*. Challenging traditional paradigms in posttraumatic pulmonary thromboembolism. *JAMA Surg* 2022;157:e216356.
- 22 Bigos R, Solomon E, Dorfman JD, Ha M. A weight- and anti-Xa-guided enoxaparin dosing protocol for venous thromboembolism prophylaxis in intensive care unit trauma patients. J Surg Res 2021;265:122–30.
- 23 Cronin BJ, Godat LN, Berndtson AE, Pham A, Kolan S, Box K, Lee JG, Costantini TW. Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients. *Burns* 2019;45:818–24.
- 24 Sanchez C, Nguyen J, Baroutjian A, Gill S, McKenney M, Elkbuli A. Venous thromboembolism chemoprophylaxis in trauma and emergency general surgery patients: a systematic review. *J Trauma Nurs* 2021;28:323–31.
- 25 Murphy PB, de Moya M, Karam B, Menard L, Holder E, Inaba K, Schellenberg M. Optimal timing of venous thromboembolic chemoprophylaxis initiation following blunt solid organ injury: meta-analysis and systematic review. *Eur J Trauma Emerg Surg* 2022;48:2039–46.
- 26 Hecht JP, Han EJ, Brandt MM, Wahl WL. Early chemoprophylaxis in severely injured trauma patients reduces risk of venous thromboembolism. *Am Surg* 2020;86:1185–93.
- 27 Schroeppel TJ, Clement LP, Douville AA, Schmoekel NH, Stassinopoulos J, Decker C, Stillman ZE, Rodriquez J, Brockman VP, Hennessy E, *et al*. Time is of the essence: impact of a more aggressive chemical venous thromboembolism prophylaxis regimen on trauma patients. *Am Surg* 2022;88:455–62.
- 28 Velmahos GC, Spaniolas K, Tabbara M, Abujudeh HH, de Moya M, Gervasini A, Alam HB. Pulmonary embolism and deep venous thrombosis in trauma: are they related?. Arch Surg 2009;144:928–32.
- 29 Knudson MM, Gomez D, Haas B, Cohen MJ, Nathens AB. Three thousand seven hundred thirty-eight posttraumatic pulmonary emboli: a new look at an old disease. *Ann Surg* 2011;254:625–32.
- 30 Van Gent J-M, Zander AL, Olson EJ, Shackford SR, Dunne CE, Sise CB, Badiee J, Schechter MS, Sise MJ. Pulmonary embolism without deep venous thrombosis: de novo or missed deep venous thrombosis? J Trauma Acute Care Surg 2014;76:1270–4.